Table 3–
Adjusted prevalence ratios and 95% CI for regimen being determined via abstraction compared with being determined via algorithm, by population characteristic
| Characteristic | N = 10,613 (%) | Age, stage and site adjusted prevalence ratio (95% CI) | Multivariable adjusted prevalence ratio (95% CI) |
|---|---|---|---|
| Age at diagnosis (years) * | |||
| 18–39 | 932 (8.8) | 1.00 (Ref) | 1.00 (Ref) |
| 40–49 | 2612 (24.6) | 0.80 (0.69, 0.93) | 0.86 (0.74, 0.99) |
| 50–64 | 4959 (46.7) | 0.72 (0.62, 0.82) | 0.77 (0.67, 0.88) |
| 65–79 | 2061 (19.4) | 0.74 (0.63, 0.87) | 0.80 (0.69, 0.94) |
| 80+ | 49 (0.5) | 1.35 (0.85, 2.15) | 1.25 (0.77, 2.02) |
| p-trend= 0.002 | p-trend = 0.01 | ||
| Race/Ethnicity | |||
| Non-Hispanic White | 6029 (56.8) | 1.00 (Ref) | 1.00 (Ref) |
| Hispanic | 1611 (15.2) | 0.93 (0.82, 1.06) | 0.92 (0.81, 1.04) |
| Non-Hispanic Black or African American | 890 (8.4) | 0.98 (0.84, 1.15) | 0.93 (0.80, 1.10) |
| Non-Hispanic Asian | 1934 (18.2) | 1.02 (0.90, 1.14) | 0.97 (0.86, 1.08) |
| Non-Hispanic Native Hawaiian or Other Pacific Islander | 92 (0.9) | 0.99 (0.63, 1.56) | 0.98 (0.61, 1.57) |
| Non-Hispanic American Indian or Alaskan Native/More than one race/other | 57 (0.5) | 0.77 (0.47, 1.28) | 0.69 (0.44, 1.09) |
| p-value = 0.77 | p-value = 0.48 | ||
| Site * | |||
| KPNC | 9885 (93.1) | 1.00 (Ref) | 1.00 (Ref) |
| KPWA | 728 (6.7) | 2.11 (1.88, 2.36) | 1.97 (1.73, 2.24) |
| p-value <0.001 | p-value < 0.001 | ||
| Median neighborhood household income a * | |||
| Q1: <$66,275 | 2652 (25.0) | 1.00 (Ref) | 1.00 (Ref) |
| Q2: $66,275-<$89,072 | 2647 (24.9) | 0.92 (0.82, 1.03) | 0.93 (0.83, 1.04) |
| Q3: $89,072-<$116,923 | 2765 (26.1) | 1.03 (0.92, 1.15) | 0.99 (0.89, 1.11) |
| Q4: >$116,923 | 2549 (24.0) | 0.77 (0.68, 0.88) | 0.76 (0.67, 0.86) |
| p-trend = 0.002 | p-trend < 0.001 | ||
| BMI at diagnosis (kg/m2) | |||
| <18.5 | 108 (1.0) | 0.93 (0.60, 1.44) | 0.88 (0.58, 1.36) |
| 18.5-<25 | 3330 (31.4) | 1.00 (Ref) | 1.00 (Ref) |
| 25-<30 | 3299 (31.1) | 0.95 (0.86, 1.06) | 0.98 (0.88, 1.09) |
| 30-<35 | 2125 (20.0) | 1.04 (0.92, 1.17) | 1.06 (0.94, 1.19) |
| 35+ | 1751 (16.5) | 1.00 (0.88, 1.14) | 1.04 (0.91, 1.18) |
| p-trend = 0.46 | p-trend = 0.29 | ||
| Charlson comorbidity index | |||
| 0 | 8015 (75.5) | 1.00 (Ref) | 1.00 (Ref) |
| 1 | 1725 (16.3) | 1.11 (0.99, 1.24) | 1.10 (0.99, 1.23) |
| 2 | 490 (4.6) | 0.98 (0.78, 1.21) | 0.95 (0.77, 1.18) |
| 3+ | 383 (3.6) | 1.28 (1.03, 1.58) | 1.27 (1.03, 1.56) |
| p-trend = 0.04 | p-trend = 0.05 | ||
| Menopausal status | |||
| Pre-menopausal | 5197 (49.0) | 1.00 (Ref) | 1.00 (Ref) |
| Post-menopausal | 5416 (51.0) | 0.95 (0.83, 1.08) | 0.96 (0.85, 1.09) |
| p-value = 0.40 | p-value = 0.56 | ||
| Year of diagnosis b * | |||
| 2004–2007 | 1306 (12.3) | 1.00 (Ref) | 1.00 (Ref) |
| 2008–2011 | 2949 (27.8) | 0.73 (0.65, 0.83) | 0.74 (0.66, 0.83) |
| 2012–2015 | 3228 (30.4) | 0.60 (0.53, 0.68) | 0.59 (0.52, 0.66) |
| 2016–2019 | 3130 (24.5) | 0.73 (0.65, 0.83) | 0.73 (0.63, 0.84) |
| p-trend <0.001 | p-trend < 0.001 | ||
| Stage * | |||
| Stage I | 3516 (33.1) | 1.00 (Ref) | 1.00 (Ref) |
| Stage II | 5796 (54.6) | 1.10 (0.99, 1.21) | 1.17 (1.06, 1.29) |
| Stage IIIA | 1301 (12.3) | 1.47 (1.29, 1.67) | 1.63 (1.43, 1.86) |
| p-trend <0.001 | p-trend < 0.001 | ||
| Grade * | |||
| Grade I | 1053 (9.9) | 1.00 (Ref) | 1.00 (Ref) |
| Grade II | 4552 (42.9) | 1.14 (0.96, 1.34) | 0.98 (0.83, 1.15) |
| Grade III | 5008 (47.2) | 1.35 (1.15, 1.59) | 1.05 (0.89, 1.25) |
| p-trend <0.001 | p-trend = 0.19 | ||
| Tumor size * | |||
| 0.1–0.5cm | 176 (1.7) | 1.00 (Ref) | 1.00 (Ref) |
| 0.5->1cm | 848 (8.0) | 0.75 (0.55, 1.01) | 0.94 (0.69, 1.27) |
| 1<−2cm | 3917 (36.9) | 0.69 (0.52, 0.90) | 0.91 (0.69, 1.20) |
| 2<−5cm | 4983 (47.0) | 0.68 (0.51, 0.90) | 0.85 (0.69, 1.20) |
| >5cm | 664 (6.3) | 0.70 (0.51, 0.97) | 0.96 (0.70, 1.32) |
| No mass or tumor found/microinvasion/other | 25 (0.2) | 2.02 (1.24, 3.29) | 2.25 (1.39, 3.64) |
| p-value <0.001 | p-value = 0.0003 | ||
| Number of nodes * | |||
| All nodes negative | 5316 (50.1) | 1.00 (Ref) | 1.00 (Ref) |
| 1–3 nodes | 3883 (36.6) | 1.06 (0.96, 1.18) | 1.22 (1.10, 1.36) |
| 4–9 nodes | 1061 (10.0) | 1.19 (0.97, 1.47) | 1.34 (1.07, 1.66) |
| 10+ nodes | 64 (0.6) | 1.67 (1.11, 2.51) | 2.07 (1.42, 3.02) |
| Positive but number unknown | 187 (1.8) | 1.73 (1.35, 2.22) | 1.60 (1.25, 2.06) |
| No nodes examined | 102 (1.0) | 1.27 (0.85, 1.88) | 1.03 (0.66, 1.61) |
| p-value <0.001 | p-value < 0.001 | ||
| Hormone-receptor positivity * | |||
| ER- and PR- | 2951 (27.8) | 1.00 (Ref) | 1.00 (Ref) |
| ER+ and/or PR+ | 7662 (72.2) | 0.84 (0.76, 0.91) | 0.93 (0.78, 1.10) |
| p-value <0.001 | p-value = 0.41 | ||
| HER2 positivity * | |||
| HER2- | 7905 (74.5) | 1.00 (Ref) | 1.00 (Ref) |
| HER2+ | 2627 (24.8) | 2.35 (2.16, 2.56) | 2.34 (2.15, 2.54) |
| Borderline | 81 (0.8) | 1.11 (0.68, 1.80) | 1.20 (0.74, 1.95) |
| p-value <0.001 | p-value < 0.001 | ||
| Surgery Type * | |||
| No surgery | 150 (1.4) | 1.00 (Ref) | 1.00 (Ref) |
| Mastectomy | 5057 (47.7) | 0.70 (0.53, 0.92) | 0.76 (0.59, 1.00) |
| Breast conserving surgery | 5406 (50.9) | 0.66 (0.50, 0.88) | 0.75 (0.57, 0.99) |
| p-value = 0.01 | p-value = 0.13 | ||
| Endocrine therapy * | |||
| No | 3432 (32.3) | 1.00 (Ref) | 1.00 (Ref) |
| Yes | 7181 (67.7) | 0.84 (0.77, 0.92) | 0.98 (0.83, 1.15) |
| p-value <0.001 | p-value = 0.77 | ||
| Radiotherapy * | |||
| No | 6018 (56.7) | 1.00 (Ref) | 1.00 (Ref) |
| Yes | 4595 (43.3) | 0.82 (0.75, 0.89) | 0.90 (0.80, 1.00) |
| p-value <0.001 | p-value = 0.06 |
a
Poverty-income ratio is a community level variable
b
Data for 2004–2006 only available for participants enrolled at KPWA and data for 2016– 2019 only available for participants enrolled at KPNC
*
Variables included in multivariable-adjusted analyses